Evotec SE (EVO) Liabilities from Discontinued Operations (2024 - 2025)
Evotec SE (EVO) reported Liabilities from Discontinued Operations of 46863.91 for Q3 2025, up 474.87% on a YoY basis from 8152.08 in Q3 2024, and up 474.87% sequentially from 8152.08 in Q3 2024.
Evotec SE (EVO) Liabilities from Discontinued Operations (2024 - 2025) Analysis & Trends
Evotec SE (EVO) has 2 years of Liabilities from Discontinued Operations data on file, last reported at 46863.91 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Evotec SE | 351.60 Mn | 351.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 46,863.91 |
| Sep 30, 2025 | 46,863.91 |
| Sep 30, 2024 | 8,152.08 |
| Sep 30, 2024 | 8,152.08 |